YOU will note arms E & F are interferon-free, VX222 400mg bid + Telaprevir bid + Ribavirin, in 46 patients for 12 weeks, with an option of adding peg/rbv after 12 weeks of IFN-free. The results are from part of the study are not ready yet for presentation so are not in this poster but we expect it soon. Vertex has 2 nucleotides (acquired from Alios) that they are studying now in phase 1 with results expected soon, within a few months, whereupon based on these results from the phase 1 nucleotide studies new studies will quickly be designed including all of the Vertex orals which in total add up to a potential of 4 oral drugs that can be utilized in such studies (telaprevir, VX222, 2 nucleotides).